Target intelligence / Profile preview

Glioblastoma amplified sequence pseudogene (No widely used canonical abbreviation for this pseudogene; "GBAS pseudogene" may occur informally, but "GBAS" more commonly refers to the protein-coding gene, not the pseudogene)

Target
No widely used canonical abbreviation for this pseudogene; "GBAS pseudogene" may occur informally, but "GBAS" more commonly refers to the protein-coding gene, not the pseudogene
Molecular classification
Other (Pseudogene)
01

Overview

The glioblastoma amplified sequence pseudogene, designated as ENSG00000262961 in the Ensembl database, is a nonfunctional genomic sequence that shares homology with the protein-coding *glioblastoma amplified sequence (GBAS)* gene (also known as NIPSNAP2), but contains mutations that prevent it from encoding a functional protein. According to the guidelines of the HUGO Gene Nomenclature Committee (HGNC), pseudogenes are sequences resembling functional genes but rendered nonfunctional by mutations such as insertions, deletions, or nonsense changes. While some pseudogenes are transcribed and can participate in gene regulation, there is no evidence that ENSG00000262961 has a defined biological or pathophysiological function. It is therefore not classified as a receptor, enzyme, transporter, or any actionable drug target. Care must be taken not to conflate this pseudogene with the functional protein-coding "glioblastoma amplified sequence" gene (GBAS/NIPSNAP2), which does have aliases and may be involved in cellular biology. ENSG00000262961 is a pseudogene, does not encode a therapeutic target, and largely exists as a nonfunctional DNA sequence homologous to the GBAS gene. It should not be confused with the actual protein-coding GBAS/NIPSNAP2 gene.

02

Biological functions

Other (No well-characterized function; may be transcriptionally active, but not protein-coding)
03

Disease associations

Other (Pseudogenes are not typically assigned disease roles, though some may be studied for regulatory or biomarker roles in cancer)

Beyond the preview

Go deeper on Glioblastoma amplified sequence pseudogene (No widely used canonical abbreviation for this pseudogene; "GBAS pseudogene" may occur informally, but "GBAS" more commonly refers to the protein-coding gene, not the pseudogene).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glioblastoma amplified sequence pseudogene (No widely used canonical abbreviation for this pseudogene; "GBAS pseudogene" may occur informally, but "GBAS" more commonly refers to the protein-coding gene, not the pseudogene).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call